Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Midodrine

Preparation Calculator

USE IF: Symptomatic orthostatic hypotension with standing BP support plan; selected ICU vasopressor weaning adjunct when supine hypertension risk is monitored and daytime-only dosing enforced.

AVOID IF: Supine hypertension or inability to monitor lying BP; dosing near sleep; baseline severe hypertension; urinary retention; acute renal context where risk outweighs benefit without nephrology alignment.

Midodrine

Peripheral α1 agonist (vasopressor, orthostatic hypotension)

AdultHypotensionAutonomicICUWardOutpatientOrthostatic

Indication

Orthostatic hypotension • Selected ICU weaning adjunct • Daytime vasoconstriction

At a glance

INDICATIONS (CORE USE)

- Symptomatic orthostatic hypotension - Vasopressor weaning (ICU adjunct, selected) - Chronic low BP states (selected patients)

ADULT DOSE (STANDARD)

2.5–10 mg PO TID during daytime Last dose several hours before bedtime Titrate to standing symptoms and BP

MAX DOSE

Typically up to ~10 mg TID (context- and response-dependent)

Route

PO

PEDIATRIC DOSE

Specialist / protocol-based only

Do not miss

Must-not-miss safety points

Major warning

- Supine hypertension (major risk) - Do NOT give near bedtime (avoid nighttime hypertension) - Monitor BP both standing and supine - Can cause bradycardia via reflex mechanisms - Not for hypertensive patients

Indications

Primary

  • Symptomatic orthostatic hypotension

Secondary

  • Vasopressor weaning (ICU adjunct)
  • Chronic low BP states (selected patients)

Dosing

STANDARD (ADULT PO)

Adult PO: 2.5–10 mg TID daytime only — last dose well before bedtime

ADULT DOSE

STANDARD (ADULT PO): - 2.5–10 mg TID during daytime

PEDIATRIC DOSE

Specialist / protocol-based

MAX DOSE

Typically up to ~10 mg TID (context-dependent)

Practical Note

- Last dose several hours before bedtime - Dose based on symptom response and standing + supine BP - Do not use as treatment for essential hypertension

Warnings

Clinical warnings

  • Supine hypertension
  • Piloerection, paresthesia, urinary retention
  • Bradycardia (reflex)
  • Hypertension if misused or with contraindicated baseline BP

Contraindications

  • Severe hypertension
  • Acute renal disease (context-dependent caution)
  • Urinary retention

Drug interactions

  • Other vasopressors / sympathomimetics → additive hypertension
  • Bradycardia-inducing drugs (β-blockers, digoxin, etc.) → additive bradycardia risk — monitor HR/BP

Special populations

Pediatrics

Specialist / protocol-based only

Pregnancy

Pregnancy /

Lactation

risk–benefit per specialist and product labeling (limited / context-specific use).

Renal impairment

Use cautiously; accumulation possible — follow labeling and titrate with BP monitoring.

Hepatic impairment

Prodrug → active metabolite; severe hepatic impairment: follow labeling / specialist.

Elderly

Monitor BP carefully (standing and supine); higher supine hypertension and bradycardia vigilance.

Administration

- Daytime dosing only - Avoid dosing close to sleep - Measure BP sitting/standing and supine when protocol requires

Monitoring

  • Monitor: - BP (standing and supine) - Symptoms (dizziness, syncope, supine headache)
  • Recheck: - After dose adjustments - Regularly in chronic use - If orthostatic symptoms persist at 48–72h on correct daytime dosing → reassess etiology and supine BP; do not continue blindly without lying BP checks
  • Hold if:
    - Supine hypertension
    - Symptomatic hypertension
    - Bradycardia

Overdose / toxicity

Clinical Picture

Hypertension Bradycardia Supine hypertension may dominate

Immediate Actions

Supportive care BP control as needed per protocol

Antidote

None specific

Decontamination

Acute overdose: poison center; supportive care and BP management.

Escalation

Severe hypertension, ischemic symptoms, or refractory bradycardia → ICU / cardiology pathways.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Always check supine BP
  • Avoid nighttime dosing

Clinical

  • Useful adjunct for selected ICU vasopressor weaning when autonomic/BP monitoring is reliable

Safety

  • Biggest error = causing supine hypertension

Pharmacy Tool

Preparation Calculator

Midodrine 2.5 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Prodrug (midodrine) → active metabolite (desglymidodrine) with longer effect than parent half-life suggests clinically - Renal excretion important

Mechanism of action

- Peripheral α1 receptor agonism → arteriolar/venular vasoconstriction → ↑ venous return and BP

Common brand names

Saudi Arabia

ProAmatine, Gutron

Global

Orvaten, Midodrine, (placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • FDA / SFDA product labeling (supine BP monitoring, dosing interval)
  • Autonomic society / orthostatic hypotension references (regional)
  • ICU vasopressor-weaning institutional protocols (where applicable)